Revenue: As of FY2025 Q2, the actual value is USD 222.72 K.

EPS: As of FY2025 Q2, the actual value is USD 3.58.

Segment Revenue

• Net Revenue: $222,722 for the three and six months ended June 30, 2025, compared to $0 for the same periods in 2024.

Operational Metrics

• Gross Margin (Loss): - $1,032,027 for the three and six months ended June 30, 2025, compared to $0 for the same periods in 2024.
• Research and Development Expenses: $61,455 for the three months ended June 30, 2025, compared to $180,297 for the same period in 2024. For the six months ended June 30, 2025, R&D expenses were $143,471 compared to $377,736 for the same period in 2024.
• Selling, General and Administrative Expenses: $1,912,900 for the three months ended June 30, 2025, compared to $1,740,803 for the same period in 2024. For the six months ended June 30, 2025, SG&A expenses were $3,852,653 compared to $3,387,416 for the same period in 2024.
• Net Income (Loss): $3,559,307 for the three months ended June 30, 2025, compared to - $2,102,327 for the same period in 2024. For the six months ended June 30, 2025, net income was $5,488,141 compared to a net loss of - $3,084,713 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $4,355,930 for the six months ended June 30, 2025, compared to - $3,528,676 for the same period in 2024.
• Net Cash Used in Investing Activities: - $1,959,758 for the six months ended June 30, 2025, compared to - $1,019,355 for the same period in 2024.
• Net Cash Provided by Financing Activities: $13,953,031 for the six months ended June 30, 2025, compared to $2,972,348 for the same period in 2024.

Unique Metrics

• FMV Adjustment for Warrants: $6,468,811 gain for the three months ended June 30, 2025, compared to $822,130 gain for the same period in 2024. For the six months ended June 30, 2025, the gain was $11,087,700 compared to $1,672,187 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to drive revenue growth from both the Securegard and Sologard projects in 2025, as well as secure manufacturing capacity for the next generation polymer-based prefillable syringes. The recent financing will support essential operating expenses and production is on track, with revenue commencing in the quarter ended June 30, 2025.
• Non-Core Business: The company is not actively working towards further amendments of the Asset Purchase Agreement with Nephron but may consider it in the future if conditions change.
• Priority: Emphasis on expanding production capacity in Hungary, including the purchase of advanced machinery and other facility upgrades to fulfill Securegard and Sologard orders and other future business opportunities.